Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescription drugs’ (INO) inventory in 2025. Inventory forecasts are based mostly on varied elements similar to the corporate’s monetary efficiency, business tendencies, and total financial situations.
Inovio is a clinical-stage biotechnology firm targeted on creating and commercializing DNA-based immunotherapies for infectious illnesses and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s presently in Section 3 scientific trials. Inovio additionally has a pipeline of different DNA-based vaccines in growth for varied infectious illnesses and most cancers indications.
